First E-Cigarette Flavor and Device Type Used: Associations With Vaping Persistence, Frequency, and Dependence in Young Adults.


Journal

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
ISSN: 1469-994X
Titre abrégé: Nicotine Tob Res
Pays: England
ID NLM: 9815751

Informations de publication

Date de publication:
14 02 2022
Historique:
received: 28 03 2021
accepted: 27 08 2021
pubmed: 31 8 2021
medline: 1 4 2022
entrez: 30 8 2021
Statut: ppublish

Résumé

Type of e-cigarette flavoring and device during first use might differentiate later e-cigarette use and dependence. This retrospective cross-sectional study examined associations of recalled first nicotine vaping device and flavor used with current vaping frequency/dependence. A young adult cohort from Los Angeles, California, USA completed web-based surveys (N = 2553). Using cross-sectional data from 971 reporting ever vaping nicotine, multivariable hurdle regressions tested associations between recalled first flavor (fruit/sweet, menthol/mint, other) and device (Juul, disposable, mod, box, pod, pen, other) vaped with past-30-day vaping status (yes/no) and frequency (1-30 days), and with any vaping dependence symptoms (yes/no) and count (1-10 symptoms). The most common first-flavor was sweet (71%); the most common first-device was a vape pen (37%), then Juul (22%). First-flavor of mint/menthol (vs. other; adjusted odds ratio [AOR]: 2.22[95% CI = 1.16 to 4.25]), and first-device mod (AOR = 2.40[95% CI = 1.34 to 4.31]) and non-Juul pod (2.64[95% CI = 1.41 to 4.92]) (vs. pen) were associated with past-30-day vaping, and twice as many vaping days (adjusted rate ratios [ARRs] range: 1.96-2.12; ps < .05). First flavor of mint/menthol (vs. other; AOR: 1.95[95% CI = 1.003 to 3.79) and first device mod, box, non-Juul pod, and other (AORs range: 2.36-4.01; ps < .05) were associated with nicotine dependence. First device Juul, mod, box, and non-Juul pod were also associated with more dependence symptoms (ARRs range:1.38-1.59; ps < .05). Exposure to mint/menthol and certain devices (mod, box, Juul, and non-Juul pods) at first e-cigarette use may be associated with more frequent e-cigarette use and nicotine dependence symptoms in young adulthood. Mint/menthol and certain devices warrant consideration in regulation of e-cigarettes based on product characteristics. Characteristics (flavor and device type) of first e-cigarette product used were associated with higher usage and more dependence. Pending replication with prospective designs, the findings suggest certain flavors (mint/menthol) and devices (pods, mods) merit consideration in regulation because of their possible link with continued use and dependence among young people.

Identifiants

pubmed: 34460934
pii: 6359789
doi: 10.1093/ntr/ntab172
pmc: PMC8842392
doi:

Substances chimiques

Flavoring Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

380-387

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA042950
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229617
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA048160
Pays : United States
Organisme : FDA HHS
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA180905
Pays : United States

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

JAMA Netw Open. 2021 Jan 4;4(1):e2032757
pubmed: 33433597
J Adolesc Health. 2018 Nov;63(5):582-586
pubmed: 30348280
Exp Clin Psychopharmacol. 2020 Oct;28(5):527-539
pubmed: 31855003
Curr Addict Rep. 2019 Jun;6(2):98-113
pubmed: 31453046
Arch Pediatr Adolesc Med. 2002 Apr;156(4):397-403
pubmed: 11929376
Drug Alcohol Depend. 2017 Sep 1;178:391-398
pubmed: 28704768
N Engl J Med. 2010 Jun 17;362(24):2295-303
pubmed: 20554984
JAMA Pediatr. 2017 Dec 1;171(12):1192-1199
pubmed: 29059261
Addict Behav. 2020 Aug;107:106403
pubmed: 32222565
Drug Alcohol Depend. 2018 Jul 1;188:109-112
pubmed: 29763848
MMWR Morb Mortal Wkly Rep. 2020 Nov 20;69(46):1736-1742
pubmed: 33211681
N Engl J Med. 2019 Jan 10;380(2):192-193
pubmed: 30554549
Curr Neuropharmacol. 2018;16(4):438-459
pubmed: 29046158
JAMA. 2015 Aug 18;314(7):700-7
pubmed: 26284721
Addict Behav. 2017 Oct;73:151-157
pubmed: 28521240
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1313-1318
pubmed: 32941416
Drug Alcohol Depend. 2019 Sep 1;202:149-155
pubmed: 31351341
PLoS One. 2018 Jan 4;13(1):e0189015
pubmed: 29300749
Int J Environ Res Public Health. 2019 Aug 20;16(16):
pubmed: 31434229
Drug Alcohol Depend. 2018 Oct 1;191:279-285
pubmed: 30165328
JAMA Netw Open. 2020 Feb 5;3(2):e1921513
pubmed: 32074292
J Youth Adolesc. 1991 Apr;20(2):149-66
pubmed: 24265004
Drug Alcohol Depend. 2019 Jan 1;194:395-400
pubmed: 30497057
Tob Control. 2020 Nov;29(6):679-686
pubmed: 31852818
Nicotine Tob Res. 2015 Oct;17(10):1242-6
pubmed: 25744966
Pediatrics. 2019 Nov;144(5):
pubmed: 31659004
Neuropsychopharmacology. 2017 Nov;42(12):2285-2291
pubmed: 28401925
Addict Behav. 2014 Sep;39(9):1372-6
pubmed: 24636739
Drug Alcohol Depend. 2017 Nov 1;180:193-199
pubmed: 28915478
Nicotine Tob Res. 2015 Feb;17(2):158-62
pubmed: 25180079
JAMA. 2019 Nov 12;322(18):1824-1827
pubmed: 31524940
N Engl J Med. 2018 Sep 20;379(12):1099-1102
pubmed: 30134127

Auteurs

James D Sargent (JD)

C. Everett Koop Institute at Dartmouth, Geisel School of Medicine, Hanover, NH, USA.

Mike Stoolmiller (M)

Oregon Research Institute, Eugene, OR, USA.

Hongying Dai (H)

Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.

Jessica L Barrington-Trimis (JL)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Institute for Addiction Science, University of Southern California, Los Angeles, CA, USA.

Rob McConnell (R)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.

Janet Audrain-McGovern (J)

Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Adam M Leventhal (AM)

Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA.
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Institute for Addiction Science, University of Southern California, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH